Merck & Co. Partners with Dragonfly on NK-Based Cancer Immunotherapies

Merck & Co. plans to develop new solid tumor cancer immunotherapies using Dragonfly Therapeutics’ T ri -specific NK cell E ngagement T herapies (TriNKET ™ ) technology platform, through a collaboration that Dragonfly said could generate for it up to $695 million per program, plus royalties.Neither the number of programs, nor the types of solid tumor malignancies, were disclosed.The collaboration grants Merck the option to license exclusive worldwide intellectual property rights t